TCRT übertreffen die 19 der letzten 33Schätzungen.
58%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
--
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
--
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
--
Alaunos Therapeutics, Inc. Common Stock earnings per share and revenue
On 12. Nov. 2025, TCRT reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Alaunos Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alaunos Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Alaunos Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Alaunos Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for Alaunos Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Alaunos Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q4 2025.